Sanofi: Timeout for Campath
Enlarge image


Sanofi: Timeout for Campath

21.08.2012 - Sanofi withdraws a cancer drug from the markets and aims for a relaunch in multiple sclerosis.

Sanofi is withdrawing its cancer drug Campath from the markets. The pharma plans to commercialise the antibody under a different name and dosing regime for multiple sclerosis – a much more lucrative indication.

The development of Campath-1H, also known under its generic name alemtuzumab, as a successful drug took years. The anti-CD52 antibody was thought to cure rheumatoid arthritis in the beginning of the 90s but failed expectations. Since 2001, it has finally been approved for chronic lymphocytic leukaemia (CLL). Since then it also washes some money into Sanofi’s subsidiary Genzyme Corp. from Cambridge (USA). But revenues have been decling over the past years. Therefore Sanofi is now aiming for fresh money and a higher pricing. In a move to prevent off-label use the drug has now been pulled from European (in mid-August) and US markets (in early September) markets.

In both regions the market authorisation applications (MAAs) for a use in multiple sclerosis are pending. According to the pharma company clearing the market should ensure that „alemtuzumab is exclusively received and used in the ongoing clinical trials.“ Obviously, Sanofi thinks that a widely merchandised drug could jeopardise these trials. Alemtuzumab awaits its repeated market entry under the name Lemtrada. However, the German society for haematology and oncology (DGHO) criticises Sanofi for playing one group of patients against another. Sanofi responded that all leukaemia patients (so far about 4.000) will benefit from free-of-charge programmes that make sure that all patients receive their much needed medicine. In Germany, according to the DGHO, these programmes run so far quite smoothly even if they mean an increased bureaucratic effort.


07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • PHARMING (NL)0.31 EUR19.23%


  • THERAMETRICS (CH)0.04 CHF-33.33%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.13 EUR48.6%
  • OREXO (S)66.00 SEK36.9%
  • ZEALAND PHARMA (DK)156.00 DKK22.4%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • TIGENIX (B)0.88 EUR-27.9%


  • KARO BIO (S)43.60 SEK5282.7%
  • CHRONTECH PHARMA (S)0.35 SEK337.5%
  • GALAPAGOS (B)38.43 EUR225.7%


  • NEOVACS (F)0.70 EUR-77.8%
  • BIOTEST (D)19.15 EUR-74.6%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 08.10.2015